ATNM Insider Trading Activity and SEC Form 4 Filings
ATNM insider trading summary
No open-market insider purchases or sales of Actinium Pharmaceuticals, Inc. (ATNM) have been reported on SEC Form 4 in the past 12 months.
Latest ATNM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 10, 2018 | Steve O'Loughlin | Principal Financial Officer | Buy | $4K (10,000 @ $0.43) |
| Dec 10, 2018 | Sandesh Seth | Chairman & CEO | Buy | $4K (10,000 @ $0.44) |
| Nov 19, 2018 | Dale L. Ludwig | Chief Scientific Officer | Buy | $4K (10,000 @ $0.45) |
| Jul 17, 2018 | Sandesh Seth | CEO | Buy | $8K (10,000 @ $0.79) |
| Jun 15, 2018 | Steve O'Loughlin | Principal Financial Officer | Buy | $6K (12,000 @ $0.50) |
| Apr 19, 2018 | Sandesh Seth | Chairman & CEO | Buy | $2K (5,000 @ $0.38) |
| Feb 28, 2018 | Ajit Shetty | Director | Buy | $10K (22,730 @ $0.43) |
| Aug 2, 2017 | Nitya G. Ray | Executive Vice President | Buy | $8K (10,000 @ $0.75) |
| Aug 2, 2017 | Sandesh Seth | Chairman & CEO | Buy | $25K (33,333 @ $0.75) |
| Jun 15, 2017 | Sandesh Seth | Chairman and CEO | Buy | $6K (5,000 @ $1.16) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.